These findings enrich the understanding of the relationship between SEs and m6A modification, shed light on the common mechanisms of IGF2BP2/IGF2BP3 on DDX21, and emphasise the meaningful values of DDX21 in AML progression. The gene discussed is IGF2BP3; the disease is acute myeloid leukemia.